Interferon alpha-2b - HanAll Biopharma

Drug Profile

Interferon alpha-2b - HanAll Biopharma

Alternative Names: Hanferon; HL031 (oral interferon alpha-2b) - HanAll Biopharma; HL143 (subcutaneous interferon alpha-2b) - HanAll Biopharma; Modified interferon-alpha - HanAll Biopharma; Resis-IFN-alpha-2b

Latest Information Update: 13 Jan 2016

Price : $50

At a glance

  • Originator Nautilus Biotech
  • Developer HanAll Biopharma; Nautilus Biotech
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hepatitis C; Hepatocellular carcinoma
  • Discontinued Cancer

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 10 Aug 2015 Phase-II development of SC interferon alpha-2b is ongoing in USA
  • 19 Jun 2012 Phase-IIa clinical trials in Hepatitis C in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top